Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases

GE Fragoulis, S Siebert, IB McInnes - Annual review of medicine, 2016 - annualreviews.org
The discovery of the biological functions of the interleukin-23/-17 axis led to the identification
of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated …

Blocking IL-17: a promising strategy in the treatment of systemic rheumatic diseases

C Rafael-Vidal, N Pérez, I Altabás, S Garcia… - International Journal of …, 2020 - mdpi.com
Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that
affect the connective tissue, characterized by the involvement of multiple organs, leading to …

Historical insights into cytokines

CA Dinarello - European journal of immunology, 2007 - Wiley Online Library
Cytokines affect nearly every biological process; these include embryonic development,
disease pathogenesis, non‐specific response to infection, specific response to antigen …

Human autoimmune diseases: a comprehensive update

L Wang, FS Wang, ME Gershwin - Journal of internal medicine, 2015 - Wiley Online Library
There have been significant advances in our understanding of human autoimmunity that
have led to improvements in classification and diagnosis and, most importantly, research …

Advances in rheumatology: new targeted therapeutics

PP Tak, JR Kalden - Arthritis research & therapy, 2011 - Springer
Abstract Treatment of inflammatory arthritides-including rheumatoid arthritis, ankylosing
spondylitis, and psoriatic arthritis-has seen much progress in recent years, partially due to …

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

S Alzabin, SM Abraham, TE Taher… - Annals of the …, 2012 - ard.bmj.com
Objectives To establish if changes in Th1/Th17 cell populations previously reported in
experimental arthritis occur in patients with rheumatoid arthritis (RA) treated with anti-tumour …

The biology behind interleukin-6 targeted interventions

X Liu, GW Jones, EH Choy… - Current opinion in …, 2016 - journals.lww.com
The biology behind interleukin-6 targeted interventions : Current Opinion in Rheumatology The
biology behind interleukin-6 targeted interventions : Current Opinion in Rheumatology Log in or …

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid …

JS Smolen, SK Agarwal, E Ilivanova, XL Xu… - Annals of the …, 2017 - ard.bmj.com
Objective Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of
rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti …

New therapies for treatment of rheumatoid arthritis

JS Smolen, D Aletaha, M Koeller, MH Weisman… - The lancet, 2007 - thelancet.com
Rheumatoid arthritis is characterised by pain, swelling, and destruction of joints, with
resultant disability. Only disease-modifying antirheumatic drugs can interfere with the …

Systemic effects of IL-17 in inflammatory arthritis

A Beringer, P Miossec - Nature Reviews Rheumatology, 2019 - nature.com
Inflammatory arthritis occurs in many diseases and is characterized by joint inflammation
and damage. However, the inflammatory state in arthritis is commonly associated with …